12 Month Price Forecast For KRON
Distance to KRON Price Forecasts
KRON Price Momentum
🤔 Considering Kronos Bio (KRON)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 9:20 AM UTC
KRON Analyst Ratings & Price Targets
Based on our analysis of 6 Wall Street analysts, KRON has a consensus that is neutral. The median price target is $2.25, with forecasts ranging from $2.25 to $2.25. Currently, there are 1 Buy ratings, 1 Hold ratings, and 0 Sell ratings.
With KRON currently trading at $1.00, the median price forecast suggests a 125.0% upside. The most optimistic forecast comes from Robert Burns at HC Wainwright & Co., projecting a 125.0% upside, while Robert Burns at HC Wainwright & Co. provides the most conservative target, suggesting a 125.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KRON Analyst Consensus
KRON Price Target Range
Latest KRON Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KRON.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 14, 2024 | Piper Sandler | Edward Tenthoff | Neutral | Downgrade | $1.00 |
| Nov 14, 2024 | TD Cowen | Floris Van Dijkum | Hold | Downgrade | $0.00 |
| Oct 8, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $6.00 |
| Aug 19, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $2.25 |
| Aug 1, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $2.25 |
| May 3, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $2.25 |
| Dec 19, 2023 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $6.00 |
| Dec 19, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $2.50 |
| Nov 27, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $9.00 |
| Aug 21, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $9.00 |
| Apr 17, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $10.00 |
| Nov 18, 2022 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $10.00 |
| Nov 10, 2022 | Goldman Sachs | Salveen Richter | Buy | Maintains | $14.00 |
| Nov 9, 2022 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $7.00 |
| Sep 14, 2022 | Berenberg | Zhiqiang Shu | Buy | Initiates | $12.00 |
| May 24, 2022 | Goldman Sachs | Salveen Richter | Buy | Maintains | $23.00 |
| May 23, 2022 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $13.00 |
| Feb 28, 2022 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $30.00 |
| Nov 10, 2021 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $36.00 |
| Jun 24, 2021 | HC Wainwright & Co. | Buy | Initiates | $0.00 |
Stocks Similar to Kronos Bio Inc
The following stocks are similar to Kronos Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Kronos Bio Inc (KRON) Financial Data
Kronos Bio Inc has a market capitalization of $59.44M with a P/E ratio of -0.5x. The company generates $8.41M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +44.2% quarter-over-quarter, while maintaining an operating margin of -649.0% and return on equity of -63.0%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Kronos Bio Inc (KRON) Company Overview
About Kronos Bio Inc
Develops therapeutics for cancer and serious diseases.
Kronos Bio, Inc. operates as a clinical-stage biopharmaceutical company, focusing on the discovery and development of innovative treatments for various cancers and serious diseases. The company generates value by advancing its product candidates through clinical trials, aiming for regulatory approval and commercialization, which can lead to significant revenue streams from sales and potential partnerships.
Founded in 2017 and based in San Mateo, California, Kronos Bio is currently developing lead candidates like KB-0742, targeting MYC-amplified solid tumors, and KB-9558 for multiple myeloma, both of which are in various stages of clinical trials.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
58
CEO
Dr. Norbert W. Bischofberger Ph.D.
Country
United States
IPO Year
2020
Website
www.kronosbio.comKronos Bio Inc (KRON) Latest News & Analysis
Norbert Bischofberger, Ph.D., is resigning as President & CEO, with Deborah Knobelman, Ph.D., likely to succeed him.
Leadership changes can signal shifts in company strategy or performance, impacting investor confidence and stock value, depending on the new leadership's vision and track record.
Kronos Bio, Inc. (KRON) reported a quarterly loss of $0.23 per share, better than the estimated loss of $0.26, and an improvement from a loss of $0.54 per share a year prior.
Kronos Bio's narrower quarterly loss than expected indicates improved financial performance, potentially boosting investor confidence and affecting stock valuation positively.
Preclinical data show that p300 KAT inhibition can effectively modulate pro-inflammatory pathways, influencing antibody and cytokine production in various models.
The effectiveness of p300 KAT inhibition in reducing inflammation signals could lead to new therapeutic developments, impacting the biotech sector's growth and investment opportunities.
Preclinical data shows that inhibiting the p300 KAT domain can reactivate p53 in HPV-driven tumors, leading to potential anti-tumor effects.
Positive preclinical results on p53 reactivation in HPV-driven tumors could drive stock prices for biotech companies involved, indicating potential for new cancer therapies and market opportunities.
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease
3 months agoKB-7898, a p300 KAT inhibitor, is the Company's first candidate for autoimmune diseases, developed using its proprietary discovery engine for transcription factor networks.
The launch of KB-7898 as a new treatment for autoimmune diseases could lead to significant market opportunities and revenue growth for the company, impacting stock performance positively.
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
3 months agoKB-9558, a p300 KAT inhibitor, demonstrated high selectivity against HPV oncoproteins E6 and E7, resulting in significant anti-tumor effects.
The efficacy of KB-9558 against HPV oncoproteins suggests potential for cancer treatment advancements, impacting biotech valuations and investor interest in related stocks.
Frequently Asked Questions About KRON Stock
What is Kronos Bio Inc's (KRON) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Kronos Bio Inc (KRON) has a median price target of $2.25. The highest price target is $2.25 and the lowest is $2.25.
Is KRON stock a good investment in 2025?
According to current analyst ratings, KRON has 1 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for KRON stock?
Wall Street analysts predict KRON stock could reach $2.25 in the next 12 months. This represents a 125.0% increase from the current price of $1.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Kronos Bio Inc's business model?
Kronos Bio, Inc. operates as a clinical-stage biopharmaceutical company, focusing on the discovery and development of innovative treatments for various cancers and serious diseases. The company generates value by advancing its product candidates through clinical trials, aiming for regulatory approval and commercialization, which can lead to significant revenue streams from sales and potential partnerships.
What is the highest forecasted price for KRON Kronos Bio Inc?
The highest price target for KRON is $2.25 from Robert Burns at HC Wainwright & Co., which represents a 125.0% increase from the current price of $1.00.
What is the lowest forecasted price for KRON Kronos Bio Inc?
The lowest price target for KRON is $2.25 from Robert Burns at HC Wainwright & Co., which represents a 125.0% increase from the current price of $1.00.
What is the overall KRON consensus from analysts for Kronos Bio Inc?
The overall analyst consensus for KRON is neutral. Out of 6 Wall Street analysts, 1 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $2.25.
How accurate are KRON stock price projections?
Stock price projections, including those for Kronos Bio Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
